MA27348A1 - Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese - Google Patents

Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese

Info

Publication number
MA27348A1
MA27348A1 MA27424A MA27424A MA27348A1 MA 27348 A1 MA27348 A1 MA 27348A1 MA 27424 A MA27424 A MA 27424A MA 27424 A MA27424 A MA 27424A MA 27348 A1 MA27348 A1 MA 27348A1
Authority
MA
Morocco
Prior art keywords
compositions containing
compounds
hiv protease
materials
synthesis
Prior art date
Application number
MA27424A
Other languages
English (en)
Inventor
Koch Stacie S Canan
Therese N Alexander
Mark R Barvian
Gary L Bolton
Frederick E Boyer Jr
Benjamin J Burke
Tod P Holler
Tanya M Jewell
Vara Prasad Venkata Na Josyula
David J Kucera
Jeff J Machak
Lennert J Mitchell Jr
Sean T Murphy
Siegfried H Reich
Donald J Skalitzky
John H Tatlock
Michael D Varney
Scott C Virgil
Stephen E Webber
Stephen T Worland
Michael Melnick
Maria A Linton
Original Assignee
Michael Melnick
Maria A Linton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michael Melnick, Maria A Linton filed Critical Michael Melnick
Publication of MA27348A1 publication Critical patent/MA27348A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : AGOURON PHARMA.CEUTICALS, INC. (Entrée en phase nationale de la demande PCT/US02/18717) Inhibiteurs de protéase du VIH, compositions les contenant, leurs utilisations pharmaceutiques et matières pour leur synthèse Des composés de formule (I), dans laquelle les variables répondent aux définitions figurant dans le présent mémoire, qui inhibent ou bloquent avantageusement l'activité biologique de la protéase du VIH, sont décrits. Ces composés, ainsi que des compositions pharmaceutiques contenant ces composés, sont utiles pour le traitement de patients ou d'hôtes infectés par le virus VIH. Des intermédiaires et procédés de synthèse pour la préparation de ces composés sont également décrits.
MA27424A 2001-06-11 2003-12-04 Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese MA27348A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29746001P 2001-06-11 2001-06-11
US29772901P 2001-06-12 2001-06-12

Publications (1)

Publication Number Publication Date
MA27348A1 true MA27348A1 (fr) 2005-06-01

Family

ID=26970163

Family Applications (2)

Application Number Title Priority Date Filing Date
MA27423A MA27347A1 (fr) 2001-06-11 2003-12-04 Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA27424A MA27348A1 (fr) 2001-06-11 2003-12-04 Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA27423A MA27347A1 (fr) 2001-06-11 2003-12-04 Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese

Country Status (27)

Country Link
US (4) US6953858B2 (fr)
EP (3) EP1739082A1 (fr)
JP (2) JP2005508867A (fr)
KR (2) KR20040023616A (fr)
CN (2) CN1599729A (fr)
AP (2) AP2003002915A0 (fr)
AR (2) AR036093A1 (fr)
AU (2) AU2002316235A2 (fr)
BR (2) BR0210358A (fr)
CA (2) CA2450265A1 (fr)
EA (2) EA200400023A1 (fr)
GE (1) GEP20063890B (fr)
HN (1) HN2002000136A (fr)
HR (2) HRP20031015A2 (fr)
IL (2) IL159022A0 (fr)
IS (2) IS7049A (fr)
MA (2) MA27347A1 (fr)
MX (2) MXPA03011397A (fr)
NO (2) NO20035489D0 (fr)
NZ (2) NZ530024A (fr)
OA (2) OA12697A (fr)
PA (2) PA8547501A1 (fr)
PE (2) PE20040241A1 (fr)
PL (1) PL366622A1 (fr)
TN (1) TNSN03130A1 (fr)
TW (1) TW200538447A (fr)
WO (2) WO2002100845A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
JP2006076882A (ja) * 2002-09-13 2006-03-23 Sumitomo Pharmaceut Co Ltd 新規なジペプチド化合物及びその医薬用途
WO2005026114A1 (fr) * 2003-09-17 2005-03-24 Pfizer Inc. Inhibiteurs de la protease du vih, compositions les contenant et leurs utilisations pharmaceutiques
JP2007513140A (ja) * 2003-12-04 2007-05-24 ファイザー インコーポレイテッド プロテアーゼの阻害剤として有用な化合物の製造方法
EP1692119A1 (fr) * 2003-12-04 2006-08-23 Pfizer Inc. Procedes pour preparer des composes utiles en tant qu'inhibiteurs de la protease
JP2007521801A (ja) * 2003-12-04 2007-08-09 ファイザー・インク 立体異性強化アミンの製造方法
WO2005056542A1 (fr) * 2003-12-09 2005-06-23 Pfizer Inc. Compositions comportant un inhibiteur de la protease du vih
JP2007519704A (ja) * 2004-01-30 2007-07-19 ファイザー・インク 治療剤の組み合わせ
WO2005082364A1 (fr) * 2004-01-30 2005-09-09 Pfizer Inc. Compositions contenant un inhibiteur de la protease de vih et un inhibiteur de l'activite de l'enzyme du cytochrome p450
WO2005121094A1 (fr) * 2004-06-09 2005-12-22 Pfizer Limited Derives de piperazine et de piperidine utilises comme agents anti-vih
WO2012158515A1 (fr) * 2011-05-13 2012-11-22 Vertex Phamaceuticals Incorporated Procédé de préparation d'inhibiteurs de la protéase
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
BR112017015497A2 (pt) 2015-01-20 2018-01-30 Arvinas, Inc. composto, e, composição
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR20230175343A (ko) 2015-03-18 2023-12-29 아비나스 오퍼레이션스, 인코포레이티드 타겟화된 단백질들의 향상된 분해를 위한 화합물들 및 방법들
EP3302482A4 (fr) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs et procédés d'utilisation associés
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
EP3512842B1 (fr) 2016-09-15 2024-01-17 Arvinas, Inc. Dérivés d'indole en tant qu'agents de dégradation des récepteurs de l'estrogène
WO2018071606A1 (fr) 2016-10-11 2018-04-19 Arvinas, Inc. Composés et procédés pour la dégradation ciblée du récepteur des androgènes
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
EP3689868B1 (fr) 2016-12-01 2023-09-27 Arvinas Operations, Inc. Dérivés de tétrahydronaphtalène et de tétrahydroisoquinoléine en tant qu'agents de dégradation des récepteurs des oestrogènes
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3559006A4 (fr) 2016-12-23 2021-03-03 Arvinas Operations, Inc. Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal
CA3047784A1 (fr) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Composes et methodes pour la degradation ciblee de polypeptides de fibrosarcome rapidement accelere
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
CN112218859A (zh) 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
WO2020041331A1 (fr) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives
EP3999182A1 (fr) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Composés ciblant la protéine tau et procédés d'utilisation associés
CN112574201B (zh) * 2019-09-29 2024-04-19 四川科伦博泰生物医药股份有限公司 芳基胺类化合物、包含其的药物组合物及其制备方法和用途
CN110803996B (zh) * 2019-11-13 2022-01-11 台州市创源工业技术有限公司 一种羟基苄胺的合成方法
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20230157998A1 (en) 2020-03-06 2023-05-25 Pfizer Inc. Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
WO2021231174A1 (fr) 2020-05-09 2021-11-18 Arvinas Operations, Inc. Procédés de fabrication d'un composé bifonctionnel, formes ultra-pures du composé bifonctionnel, et formes posologiques les comprenant
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6418260A (en) * 1987-07-14 1989-01-23 Sanyo Electric Co Transistor
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
CA2056911C (fr) * 1990-12-11 1998-09-22 Yuuichi Nagano Inhibiteurs de la protease de vih
AU647239B2 (en) * 1991-02-08 1994-03-17 Sankyo Company Limited New beta-amino- alpha-hydroxycarboxylic acids and their use
WO1993013066A1 (fr) 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Amides cycliques d'acides 3-amino-2-hydroxy-carboxyliques utilises comme inhibiteurs de la protease du vih
DE69322127T2 (de) 1992-05-13 1999-06-24 Japan Energy Corp., Tokio/Tokyo Verfahren zur Herstellung von Peptidderivaten und ihrer Salze
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
FI933472A (fi) * 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
DE69524527D1 (de) 1994-10-14 2002-01-24 Japan Energy Corp AIDS-hemmende Arzneizubereitung und Verfahren
JPH08259532A (ja) 1995-03-24 1996-10-08 Japan Energy Corp ペプチド様化合物又はその薬理的に許容される塩
US5932550A (en) 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US6222043B1 (en) * 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
JPH1087489A (ja) 1996-09-13 1998-04-07 Sankyo Co Ltd Ａｈｐｂａ構造含有ジペプチド化合物を有効成分とする医薬
JPH10101654A (ja) 1996-10-02 1998-04-21 Japan Energy Corp 新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途
JPH10182601A (ja) * 1996-12-27 1998-07-07 Japan Energy Corp 新規なジペプチド化合物又はその薬理的に許容される塩及びその医薬用途
AR012374A1 (es) 1997-04-15 2000-10-18 Smithkline Beecham Corp Inhibidores de proteasas, composiones farmaceuticas y usos para la preparacion de medicamentos.
US6673772B2 (en) 1999-01-14 2004-01-06 Sumitomo Pharmaceuticals Company Limited Dipeptide compounds and their use as antiviral agents
WO2000048466A2 (fr) 1999-02-19 2000-08-24 Oklahoma Medical Research Foundation Inhibiteurs de protease surmontant la resistance medicamenteuse
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
WO2003035650A1 (fr) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
JP2003119137A (ja) 2001-10-10 2003-04-23 Japan Tobacco Inc Ｈｉｖ阻害剤
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
AU2002349675A1 (en) 2001-12-05 2003-06-17 Shionogi And Co., Ltd. Derivative having hiv integrase inhibitory activity
JP2005515206A (ja) 2001-12-12 2005-05-26 ブリストル−マイヤーズ　スクイブ　カンパニー Ｈｉｖインテグラーゼ・インヒビター
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
TW200306192A (en) 2002-01-18 2003-11-16 Bristol Myers Squibb Co Tricyclic 2-pyrimidone compounds useful as HIV reverse transcriptase inhibitors
WO2005026114A1 (fr) * 2003-09-17 2005-03-24 Pfizer Inc. Inhibiteurs de la protease du vih, compositions les contenant et leurs utilisations pharmaceutiques
JP2007513140A (ja) * 2003-12-04 2007-05-24 ファイザー インコーポレイテッド プロテアーゼの阻害剤として有用な化合物の製造方法

Also Published As

Publication number Publication date
EP1448539A1 (fr) 2004-08-25
TNSN03130A1 (fr) 2005-12-23
GEP20063890B (en) 2006-08-10
AP1770A (en) 2007-08-22
AR036046A1 (es) 2004-08-04
US20030153507A1 (en) 2003-08-14
US20030225071A1 (en) 2003-12-04
EP1409466A2 (fr) 2004-04-21
EA200400026A1 (ru) 2004-04-29
IS7050A (is) 2003-11-21
OA12696A (en) 2006-06-22
CN1599729A (zh) 2005-03-23
PA8547501A1 (es) 2003-02-14
AU2002316235A2 (en) 2002-12-23
JP2005508867A (ja) 2005-04-07
PE20040479A1 (es) 2004-09-20
AU2002345644B2 (en) 2006-08-10
PL366622A1 (en) 2005-02-07
WO2002100845A1 (fr) 2002-12-19
CN1622942A (zh) 2005-06-01
EA008169B1 (ru) 2007-04-27
AU2002345644A2 (en) 2002-12-23
OA12697A (en) 2006-06-21
WO2002100844A2 (fr) 2002-12-19
PE20040241A1 (es) 2004-04-26
MXPA03011336A (es) 2004-12-06
EA200400023A1 (ru) 2004-06-24
BR0210358A (pt) 2004-06-22
US20070021354A1 (en) 2007-01-25
HRP20031014A2 (en) 2005-10-31
US6953858B2 (en) 2005-10-11
HN2002000136A (es) 2003-07-31
CA2450265A1 (fr) 2002-12-19
NZ530024A (en) 2005-10-28
NO20035489D0 (no) 2003-12-10
AU2002345644C1 (en) 2002-12-23
MXPA03011397A (es) 2005-03-07
EP1739082A1 (fr) 2007-01-03
MA27347A1 (fr) 2005-06-01
WO2002100844A3 (fr) 2003-03-06
IL159076A0 (en) 2004-05-12
CN100338044C (zh) 2007-09-19
NZ530023A (en) 2005-10-28
BR0210344A (pt) 2004-07-13
HRP20031015A2 (en) 2005-10-31
US20050250707A1 (en) 2005-11-10
KR20040023616A (ko) 2004-03-18
PA8547601A1 (es) 2003-12-30
IS7049A (is) 2003-11-21
AP2003002915A0 (en) 2003-12-31
US7179918B2 (en) 2007-02-20
KR20040035601A (ko) 2004-04-29
IL159022A0 (en) 2004-05-12
NO20035488D0 (no) 2003-12-10
WO2002100845A8 (fr) 2003-03-20
TW200538447A (en) 2005-12-01
AR036093A1 (es) 2004-08-11
CA2450269A1 (fr) 2002-12-19
AP2003002916A0 (en) 2003-12-31
JP2004534061A (ja) 2004-11-11

Similar Documents

Publication Publication Date Title
MA27348A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN04156A1 (fr) Pyridinones substituees servant de modulateurs de la map-kinase p38
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA26956A1 (fr) Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases.
MA28011A1 (fr) Derives de piperazine et leur utilisation en tant qu'agents therapeutiques
TNSN05250A1 (fr) Pyrimidinones substituees
MA28008A1 (fr) Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
MA26877A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
MA27156A1 (fr) NUCLEOSIDES 3- β-D-RIBOFURANOSYLTHIAZOLO[4,5-d] PYRIDIMINE ET LES UTILISATIONS DE CELLES-CI
MA31894B1 (fr) Composes organiques
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
MA27093A1 (fr) Derives de sulfonamides, leur preparation et leur application comme medicaments.
MA27716A1 (fr) 4-aminopyrimidine-5-one
MA27887A1 (fr) Dicetopiperazines substituees et leur utilisation comme antagonistes de l'ocytocine
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
TNSN00250A1 (fr) Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant
TW200800966A (en) Beta-secretase modulators and methods of use
DE60139409D1 (de) Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH